TY  - JOUR
AU  - Macut, Đuro
AU  - Opalić, Milica
AU  - Popović, Bojana
AU  - Ognjanović, Sanja
AU  - Bjekić-Macut, Jelica
AU  - Livadas, Sarantis
AU  - Petrović, Tijana
AU  - Hrnčić, Dragan
AU  - Stanojlović, Olivera
AU  - Vojnović Milutinović, Danijela
AU  - Micić, Dragan
AU  - Mastorakos, George
PY  - 2023
UR  - http://radar.ibiss.bg.ac.rs/handle/123456789/6329
AB  - Endocrine disruptors (EDs) are considered to have an impact on the function of reproductive axis at  different levels as well on reproductive organs in both sexes. Complexity of female reproductive system influenced with various stressors including EDs lead to morphological and functional alterations. This is resulting in modulation of neuroendocrine regulation with consequent developmental irregularities and derangements, causative infertility, endometriosis as well as premature ovarian insufficiency or polycystic ovary syndrome. A number of experimental clues was obtained on female animal models using various EDs such as synthetic estrogens and phytoestrogens, neurotransmitters, pesticides or various chemicals. These substances lead towards consequent derangement of the neuroendocrine control of reproduction from early phases of reproductive development towards different phases of adult reproductive period. This text will address some novel insights into the effects of EDs on neuroendocrine regulation of gonadal axis, effects on ovaries as well on endometrium during implantation period.
PB  - Bucharest: Acta Endocrinologica Foundation
T2  - Acta Endocrinologica (Bucharest)
T1  - The Effects of Endocrine Disruptors on Female Gonadal Axis: an Update
IS  - 1
VL  - 19
DO  - 10.4183/aeb.2023.81
SP  - 81
EP  - 86
ER  - 

@article{
author = "Macut, Đuro and Opalić, Milica and Popović, Bojana and Ognjanović, Sanja and Bjekić-Macut, Jelica and Livadas, Sarantis and Petrović, Tijana and Hrnčić, Dragan and Stanojlović, Olivera and Vojnović Milutinović, Danijela and Micić, Dragan and Mastorakos, George",
year = "2023",
abstract = "Endocrine disruptors (EDs) are considered to have an impact on the function of reproductive axis at  different levels as well on reproductive organs in both sexes. Complexity of female reproductive system influenced with various stressors including EDs lead to morphological and functional alterations. This is resulting in modulation of neuroendocrine regulation with consequent developmental irregularities and derangements, causative infertility, endometriosis as well as premature ovarian insufficiency or polycystic ovary syndrome. A number of experimental clues was obtained on female animal models using various EDs such as synthetic estrogens and phytoestrogens, neurotransmitters, pesticides or various chemicals. These substances lead towards consequent derangement of the neuroendocrine control of reproduction from early phases of reproductive development towards different phases of adult reproductive period. This text will address some novel insights into the effects of EDs on neuroendocrine regulation of gonadal axis, effects on ovaries as well on endometrium during implantation period.",
publisher = "Bucharest: Acta Endocrinologica Foundation",
journal = "Acta Endocrinologica (Bucharest)",
title = "The Effects of Endocrine Disruptors on Female Gonadal Axis: an Update",
number = "1",
volume = "19",
doi = "10.4183/aeb.2023.81",
pages = "81-86"
}

Macut, Đ., Opalić, M., Popović, B., Ognjanović, S., Bjekić-Macut, J., Livadas, S., Petrović, T., Hrnčić, D., Stanojlović, O., Vojnović Milutinović, D., Micić, D.,& Mastorakos, G.. (2023). The Effects of Endocrine Disruptors on Female Gonadal Axis: an Update. in Acta Endocrinologica (Bucharest)
Bucharest: Acta Endocrinologica Foundation., 19(1), 81-86.
https://doi.org/10.4183/aeb.2023.81

Macut Đ, Opalić M, Popović B, Ognjanović S, Bjekić-Macut J, Livadas S, Petrović T, Hrnčić D, Stanojlović O, Vojnović Milutinović D, Micić D, Mastorakos G. The Effects of Endocrine Disruptors on Female Gonadal Axis: an Update. in Acta Endocrinologica (Bucharest). 2023;19(1):81-86.
doi:10.4183/aeb.2023.81 .

Macut, Đuro, Opalić, Milica, Popović, Bojana, Ognjanović, Sanja, Bjekić-Macut, Jelica, Livadas, Sarantis, Petrović, Tijana, Hrnčić, Dragan, Stanojlović, Olivera, Vojnović Milutinović, Danijela, Micić, Dragan, Mastorakos, George, "The Effects of Endocrine Disruptors on Female Gonadal Axis: an Update" in Acta Endocrinologica (Bucharest), 19, no. 1 (2023):81-86,
https://doi.org/10.4183/aeb.2023.81 . .

TY  - JOUR
AU  - Bjekić-Macut, Jelica
AU  - Vukašin, Tamara
AU  - Velija-Ašimi, Zelija
AU  - Bureković, Azra
AU  - Zdravković, Marija
AU  - Andrić, Zoran
AU  - Branković, Marija
AU  - Crevar-Marinović, Slobodanka
AU  - Mandić, Tatjana
AU  - Stanojlović, Olivera
AU  - Vojnović-Milutinović, Danijela
AU  - Livadas, Sarantis
AU  - Mastorakos, George
PY  - 2021
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/4307
AB  - Polycystic ovary syndrome (PCOS) is a frequent endocrine disease in women during reproductive period. It is considered a complex metabolic disorder with long-term metabolic, as well as reproductive consequences. Main pathophysiological pathways are related to the increased androgen levels and insulin resistance. Nowadays, genetic origins of PCOS are acknowledged, with numerous genes involved in the pathogenesis of hyperandrogenemia, insulin resistance, inflammation and disturbed folliculogenesis. Rotterdam diagnostic criteria are most widely accepted and four PCOS phenotypes have been recognized. Metabolic abnormalities are more common in phenotypes 1 and 2. Women with classic PCOS are more obese and typically have central type of obesity, more prevalently displaying dyslipidemia, insulin resistance and metabolic syndrome that could be associated with an increased risk of cardiovascular complications during life. Heterogeneity of phenotypes demands an individualized approach in the treatment of women with PCOS. Metabolic therapies involve a lifestyle intervention followed by the introduction of insulin sensitizers including metformin and inositols, glucagon-like peptide 1 receptor agonists (GLP-1 RA), as recently sodium glucose contransporter-2 (SGLT2) inhibitors. Addition of an insulin sensitizer to the standard infertility therapy such as CC improves ovulation and pregnancy rates. Our current review analyzes the contemporary knowledge of PCOS etiology and etiopathogenesis, its cardiometabolic risks and their outcomes, as well as therapeutic advances for women with PCOS.
PB  - Bentham Science Publishers
T2  - Current Pharmaceutical Design
T1  - Polycystic Ovary Syndrome: A Contemporary Clinical Approach
VL  - 27
DO  - 10.2174/1381612827666210119104721
SP  - 1
EP  - 9
ER  - 

@article{
author = "Bjekić-Macut, Jelica and Vukašin, Tamara and Velija-Ašimi, Zelija and Bureković, Azra and Zdravković, Marija and Andrić, Zoran and Branković, Marija and Crevar-Marinović, Slobodanka and Mandić, Tatjana and Stanojlović, Olivera and Vojnović-Milutinović, Danijela and Livadas, Sarantis and Mastorakos, George",
year = "2021",
abstract = "Polycystic ovary syndrome (PCOS) is a frequent endocrine disease in women during reproductive period. It is considered a complex metabolic disorder with long-term metabolic, as well as reproductive consequences. Main pathophysiological pathways are related to the increased androgen levels and insulin resistance. Nowadays, genetic origins of PCOS are acknowledged, with numerous genes involved in the pathogenesis of hyperandrogenemia, insulin resistance, inflammation and disturbed folliculogenesis. Rotterdam diagnostic criteria are most widely accepted and four PCOS phenotypes have been recognized. Metabolic abnormalities are more common in phenotypes 1 and 2. Women with classic PCOS are more obese and typically have central type of obesity, more prevalently displaying dyslipidemia, insulin resistance and metabolic syndrome that could be associated with an increased risk of cardiovascular complications during life. Heterogeneity of phenotypes demands an individualized approach in the treatment of women with PCOS. Metabolic therapies involve a lifestyle intervention followed by the introduction of insulin sensitizers including metformin and inositols, glucagon-like peptide 1 receptor agonists (GLP-1 RA), as recently sodium glucose contransporter-2 (SGLT2) inhibitors. Addition of an insulin sensitizer to the standard infertility therapy such as CC improves ovulation and pregnancy rates. Our current review analyzes the contemporary knowledge of PCOS etiology and etiopathogenesis, its cardiometabolic risks and their outcomes, as well as therapeutic advances for women with PCOS.",
publisher = "Bentham Science Publishers",
journal = "Current Pharmaceutical Design",
title = "Polycystic Ovary Syndrome: A Contemporary Clinical Approach",
volume = "27",
doi = "10.2174/1381612827666210119104721",
pages = "1-9"
}

Bjekić-Macut, J., Vukašin, T., Velija-Ašimi, Z., Bureković, A., Zdravković, M., Andrić, Z., Branković, M., Crevar-Marinović, S., Mandić, T., Stanojlović, O., Vojnović-Milutinović, D., Livadas, S.,& Mastorakos, G.. (2021). Polycystic Ovary Syndrome: A Contemporary Clinical Approach. in Current Pharmaceutical Design
Bentham Science Publishers., 27, 1-9.
https://doi.org/10.2174/1381612827666210119104721

Bjekić-Macut J, Vukašin T, Velija-Ašimi Z, Bureković A, Zdravković M, Andrić Z, Branković M, Crevar-Marinović S, Mandić T, Stanojlović O, Vojnović-Milutinović D, Livadas S, Mastorakos G. Polycystic Ovary Syndrome: A Contemporary Clinical Approach. in Current Pharmaceutical Design. 2021;27:1-9.
doi:10.2174/1381612827666210119104721 .

Bjekić-Macut, Jelica, Vukašin, Tamara, Velija-Ašimi, Zelija, Bureković, Azra, Zdravković, Marija, Andrić, Zoran, Branković, Marija, Crevar-Marinović, Slobodanka, Mandić, Tatjana, Stanojlović, Olivera, Vojnović-Milutinović, Danijela, Livadas, Sarantis, Mastorakos, George, "Polycystic Ovary Syndrome: A Contemporary Clinical Approach" in Current Pharmaceutical Design, 27 (2021):1-9,
https://doi.org/10.2174/1381612827666210119104721 . .

TY  - JOUR
AU  - Macut, Đuro
AU  - Mladenović, Violeta
AU  - Bjekić-Macut, Jelica
AU  - Livadas, Sarantis
AU  - Stanojlović, Olivera
AU  - Hrnčić, Dragan
AU  - Rašić-Marković, Aleksandra
AU  - Vojnović-Milutinović, Danijela
AU  - Andrić, Zoran
PY  - 2020
UR  - http://www.eurekaselect.com/172346/article
UR  - http://www.ncbi.nlm.nih.gov/pubmed/31146668
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/3969
AB  - Polycystic ovary syndrome (PCOS) is a common endocrine disease in women during reproductive age. It was shown that PCOS women are with high risk for dyslipidemia, glucose intolerance, type 2 diabetes and metabolic syndrome. These factors are considered to represent traditional risk factors for the occurrence of cardiovascular disease. Observed increased risk for hypertension in PCOS women seems to be associated with insulin resistance and hyperinsulinemia. Both conditions interfere with the endothelium-dependent vasodilatation mechanisms causing vascular muscle wall hypertrophy. Obesity and insulin resistance are considered key factors for the alteration of blood pressure in PCOS women. Higher cardiovascular risk is implicated in PCOS with aging and its consequent association with both systolic and diastolic blood pressure. The elements of renin-angiotensin-aldosterone system (RAAS) have an impact on endothelial dysfunction as a marker of cardiovascular damage that could be modified is women with PCOS. Androgens and components of RAAS are involved in the process of atherogenesis in PCOS women. Therefore, it is hypothesized that spironolactone treatment could ameliorate endothelial dysfunction in PCOS women. Recently it was shown that telmisartan, angiotensin II receptor antagonist poses insulinsensitizing capacity to activate PPAR gamma and mediate favorable metabolic and reproductive effects in hypertensive PCOS women.
PB  - Bentham Science Publishers Ltd.
T2  - Current Hypertension Reviews
T1  - Hypertension in Polycystic Ovary Syndrome: Novel Insights.
IS  - 1
VL  - 16
DO  - 10.2174/1573402115666190531071422
SP  - 55
EP  - 60
ER  - 

@article{
author = "Macut, Đuro and Mladenović, Violeta and Bjekić-Macut, Jelica and Livadas, Sarantis and Stanojlović, Olivera and Hrnčić, Dragan and Rašić-Marković, Aleksandra and Vojnović-Milutinović, Danijela and Andrić, Zoran",
year = "2020",
abstract = "Polycystic ovary syndrome (PCOS) is a common endocrine disease in women during reproductive age. It was shown that PCOS women are with high risk for dyslipidemia, glucose intolerance, type 2 diabetes and metabolic syndrome. These factors are considered to represent traditional risk factors for the occurrence of cardiovascular disease. Observed increased risk for hypertension in PCOS women seems to be associated with insulin resistance and hyperinsulinemia. Both conditions interfere with the endothelium-dependent vasodilatation mechanisms causing vascular muscle wall hypertrophy. Obesity and insulin resistance are considered key factors for the alteration of blood pressure in PCOS women. Higher cardiovascular risk is implicated in PCOS with aging and its consequent association with both systolic and diastolic blood pressure. The elements of renin-angiotensin-aldosterone system (RAAS) have an impact on endothelial dysfunction as a marker of cardiovascular damage that could be modified is women with PCOS. Androgens and components of RAAS are involved in the process of atherogenesis in PCOS women. Therefore, it is hypothesized that spironolactone treatment could ameliorate endothelial dysfunction in PCOS women. Recently it was shown that telmisartan, angiotensin II receptor antagonist poses insulinsensitizing capacity to activate PPAR gamma and mediate favorable metabolic and reproductive effects in hypertensive PCOS women.",
publisher = "Bentham Science Publishers Ltd.",
journal = "Current Hypertension Reviews",
title = "Hypertension in Polycystic Ovary Syndrome: Novel Insights.",
number = "1",
volume = "16",
doi = "10.2174/1573402115666190531071422",
pages = "55-60"
}

Macut, Đ., Mladenović, V., Bjekić-Macut, J., Livadas, S., Stanojlović, O., Hrnčić, D., Rašić-Marković, A., Vojnović-Milutinović, D.,& Andrić, Z.. (2020). Hypertension in Polycystic Ovary Syndrome: Novel Insights.. in Current Hypertension Reviews
Bentham Science Publishers Ltd.., 16(1), 55-60.
https://doi.org/10.2174/1573402115666190531071422

Macut Đ, Mladenović V, Bjekić-Macut J, Livadas S, Stanojlović O, Hrnčić D, Rašić-Marković A, Vojnović-Milutinović D, Andrić Z. Hypertension in Polycystic Ovary Syndrome: Novel Insights.. in Current Hypertension Reviews. 2020;16(1):55-60.
doi:10.2174/1573402115666190531071422 .

Macut, Đuro, Mladenović, Violeta, Bjekić-Macut, Jelica, Livadas, Sarantis, Stanojlović, Olivera, Hrnčić, Dragan, Rašić-Marković, Aleksandra, Vojnović-Milutinović, Danijela, Andrić, Zoran, "Hypertension in Polycystic Ovary Syndrome: Novel Insights." in Current Hypertension Reviews, 16, no. 1 (2020):55-60,
https://doi.org/10.2174/1573402115666190531071422 . .

TY  - JOUR
AU  - Macut, Đuro
AU  - Bjekić-Macut, Jelica
AU  - Livadas, Sarantis
AU  - Stanojlović, Olivera
AU  - Hrnčić, Dragan
AU  - Rašić-Marković, Aleksandra
AU  - Vojnović-Milutinović, Danijela
AU  - Mladenović, Violeta
AU  - Andrić, Zoran
PY  - 2019
UR  - http://www.eurekaselect.com/169068/article
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/3308
AB  - Polycystic ovary syndrome (PCOS) is the most common endocrine disease in women during the reproductive period. True PCOS phenotype is prone to develop metabolic consequences during life. Obese PCOS women with insulin resistance are carrying a risk for developing type 2 diabetes, and influencing liver function by generating liver steatosis and nonalcoholic fatty liver disease (NAFLD). Moreover, serum testosterone of over 3 nmol/L is associated with at least two-fold higher risk for the development of NAFLD in PCOS women. Numerous genes involved in the pathogenesis of hyperandrogenism, insulin resistance and inflammation are associated with the development of NAFLD in PCOS women. Liver biopsy is not considered as the first line procedure for the diagnosis of liver damage in a prevalent condition as PCOS. Therefore, simple and reliable surrogate markers as serum aminotransferases levels or surrogate indexes (i.e. fatty liver index and NAFLD-fatty liver score) could be used for the assessment of fatty liver in PCOS women. First line therapeutic approach for NAFLD in PCOS includes a change in lifestyle that implies dietary regiment and physical activity but without well-defined protocols. Second line therapy considers addition of drugs on the established lifestyle change. Metformin remains the drug of choice for reduction of insulin resistance and liver enzymes level. Liraglutide, glucagon-like peptide-1 receptor agonists, showed favorable effects on the reduction of liver fat content and visceral adipose tissue in overweight women with PCOS. Current review analyzes the impact of metabolic risk factors, diagnostic approach and management options on NAFLD in women with PCOS.
T2  - Current Pharmaceutical Design
T1  - Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome
IS  - 38
VL  - 24
DO  - 10.2174/1381612825666190117100751
SP  - 4593
EP  - 4597
ER  - 

@article{
author = "Macut, Đuro and Bjekić-Macut, Jelica and Livadas, Sarantis and Stanojlović, Olivera and Hrnčić, Dragan and Rašić-Marković, Aleksandra and Vojnović-Milutinović, Danijela and Mladenović, Violeta and Andrić, Zoran",
year = "2019",
abstract = "Polycystic ovary syndrome (PCOS) is the most common endocrine disease in women during the reproductive period. True PCOS phenotype is prone to develop metabolic consequences during life. Obese PCOS women with insulin resistance are carrying a risk for developing type 2 diabetes, and influencing liver function by generating liver steatosis and nonalcoholic fatty liver disease (NAFLD). Moreover, serum testosterone of over 3 nmol/L is associated with at least two-fold higher risk for the development of NAFLD in PCOS women. Numerous genes involved in the pathogenesis of hyperandrogenism, insulin resistance and inflammation are associated with the development of NAFLD in PCOS women. Liver biopsy is not considered as the first line procedure for the diagnosis of liver damage in a prevalent condition as PCOS. Therefore, simple and reliable surrogate markers as serum aminotransferases levels or surrogate indexes (i.e. fatty liver index and NAFLD-fatty liver score) could be used for the assessment of fatty liver in PCOS women. First line therapeutic approach for NAFLD in PCOS includes a change in lifestyle that implies dietary regiment and physical activity but without well-defined protocols. Second line therapy considers addition of drugs on the established lifestyle change. Metformin remains the drug of choice for reduction of insulin resistance and liver enzymes level. Liraglutide, glucagon-like peptide-1 receptor agonists, showed favorable effects on the reduction of liver fat content and visceral adipose tissue in overweight women with PCOS. Current review analyzes the impact of metabolic risk factors, diagnostic approach and management options on NAFLD in women with PCOS.",
journal = "Current Pharmaceutical Design",
title = "Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome",
number = "38",
volume = "24",
doi = "10.2174/1381612825666190117100751",
pages = "4593-4597"
}

Macut, Đ., Bjekić-Macut, J., Livadas, S., Stanojlović, O., Hrnčić, D., Rašić-Marković, A., Vojnović-Milutinović, D., Mladenović, V.,& Andrić, Z.. (2019). Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome. in Current Pharmaceutical Design, 24(38), 4593-4597.
https://doi.org/10.2174/1381612825666190117100751

Macut Đ, Bjekić-Macut J, Livadas S, Stanojlović O, Hrnčić D, Rašić-Marković A, Vojnović-Milutinović D, Mladenović V, Andrić Z. Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome. in Current Pharmaceutical Design. 2019;24(38):4593-4597.
doi:10.2174/1381612825666190117100751 .

Macut, Đuro, Bjekić-Macut, Jelica, Livadas, Sarantis, Stanojlović, Olivera, Hrnčić, Dragan, Rašić-Marković, Aleksandra, Vojnović-Milutinović, Danijela, Mladenović, Violeta, Andrić, Zoran, "Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome" in Current Pharmaceutical Design, 24, no. 38 (2019):4593-4597,
https://doi.org/10.2174/1381612825666190117100751 . .